Cheryl V. Reicin
Cheryl V. Reicin
Partner at Torys LLP
(416) 865-7373
(416) 865-7380
79 Wellington St W, Suite 3000, Box 270, TD Ctr, Toronto, ON
Year called to bar: 1985 (New York); 1989 (Massachusetts)
Practice focuses on biotechnology, medical device, health information and other technology-based companies, and representation of private equity/venture capital funds and investment banks that fund such companies, including academic medical centres and universities, primarily in the US, Canada and Israel. Assists companies in formulating domestic and international growth strategies and in sourcing capital. Advises on venture and later-stage financings, IPOs, mergers & acquisitions, licensing transactions and joint ventures or alliances with strategic partners. Also coordinates domestic and international structuring to dovetail with intellectual property and tax planning and regulatory strategy. Directorships include The Hospital for Sick Children (Trustee); Genesis, incubator for social entrepreneurship (Chair and Founder); and Health Technologies Fund (External Review Panel), among others. New York Bar, 1985. Massachusetts Bar, 1989. JD, 1984, Harvard Law School. BA, 1980 (summa cum laude), Barnard College, Columbia University.
Cheryl V. Reicin is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Cheryl V. Reicin is also listed in the following publication(s)
Read more about Cheryl V. Reicin in ...
Health sciences are in the pink: renewed interest in life sciences goes beyond COVID
Investors, government and companies are realizing the value and viability of the sector
Canada’s leading biotechnology lawyers
Lexpert presents the Canada’s leading biotechnology lawyers based on the results of our comprehensive yearly peer survey
On July 17, 2017, Norgine B.V., a European specialist pharmaceutical company, acquired all issued and outstanding shares of Merus Labs International Inc. (Merus), pursuant to a plan of arrangement for $1.65 per common share in cash, including the assumption of all debt obligations, for a total enterprise value of approximately $342 million.
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.